SNMC (Stronger Neo-Minophagen C ) for Acute Hepatitis Post Transarterial Chemoembolization Therapy
Status:
Completed
Trial end date:
2019-05-28
Target enrollment:
Participant gender:
Summary
A glycyrrhizin-containing product, Stronger Neo-Minophagen C TM (SNMC; Minophagen
Pharmaceutical Co.Ltd.,Tokyo,Japan),is widely used in Japan for suppression of hepatitis
activity and for prevention of disease progression in patients with hepatitis B virus- and
HCV-induced chronic hepatitis. In Taiwan, SNMC has been licensed by Taiwan Food and Drug
Administration for the indication of maintain hepatic function. Glycyrrhizin has been
reported to mitigate hepatic inflammation by suppressing elevated alanine
aminotransferase(ALT) levels and preventing disease progression. The effect of SNMC on acute
deterioration of hepatic function following transarterial chemoembolization (TACE) was still
unknown. This study aimed to evaluate the effect of SNMC on acute deterioration of hepatic
function following TACE.